The Santa Clara, Calif.-based company said it would plow additional resources into FDA-approved Horizant (gabapentin enacarbil) in restless leg syndrome (RLS) and postherpetic neuralgia (PN) after ending a troubled partnership with GlaxoSmithKline plc (GSK) at the end of April and regaining full rights to the drug

GlaxoSmithKline plc (London) A*STAR's Institute of Chemical and Engineering Sciences (Singapore) ND Five-year agreement to develop new evidence-based formulations specifically for emerging markets EBFs are medicines reformulated to provide additional patient benefit 4/10/13 GlaxoSmithKline plc (London) Avalon Ventures $495 Deal to launch up to 10 early stage life science companies Avalon will provide up to $30M, while GSK will contribute seed funding, research and development support and success

Ltd. (Tokyo) ND ArQule regained worldwide rights to compounds covered under its AKT collaboration, including lead compound ARQ 092 The companies remain partnered on late-stage tyrosine kinase inhibitor tivantinib 4/2/13 Impax Pharmaceuticals (Hayward, Calif.; division of Impax Laboratories Inc.) GlaxoSmithKline plc (London) ND Terminated collaboration for the development and commercialization of Rytary outside the U.S

GlaxoSmithKline plc (London) ND Collaboration in which to acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb (lapitinib), a treatment for advanced or metastatic breast cancer Terms were not disclosed 4/10/13 OPKO Health Inc. (Miami) OAO Pharmsynthez (Russia) ND Partnership to develop and market several OPKO products for sale in Russia and certain other Eastern European countries OPKO acquired about a 10% stake in OAO 4/19/13 Paragon

plc is paying $1 billion for a 21 percent stake in Theravance Inc.'s future royalty streams from four drugs that are partnered with London-based GlaxoSmithKline plc

filed for a re-hearing en banc in the appeal case, in which the Court of Appeals for the Federal Circuit recently upheld the District Court's judgment in favor of GlaxoSmithKline plc, of London, Genmab's partner on Arzerra (ofatumumab...XenoPort reacquired from London-based GlaxoSmithKline plc all commercialization rights to Horizant early this month

OncoMed Pharmaceuticals Inc., of Redwood City, Calif., began a Phase Ib/II trial of its anti-Notch2/3 antibody (OMP-59R5), triggering an $8 million milestone payment from GlaxoSmithKline plc, of London

and GlaxoSmithKline plc will pay generous dividends over the next decade

A combination LAMA/LABA inhaler is a logical development since standard treatment of COPD begins with a product like Spiriva, and then advances to combination treatment, such as Spiriva plus Symbicort (formoterol and budesonide, AstraZeneca plc) or Advair (fluticasone/salmeterol, GlaxoSmithKline plc...The market for COPD is estimated at more than $8 billion and growing, and companies like GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co

and GlaxoSmithKline plc will pay generous dividends over the next decade

Few of the pundits and tea-leaf readers handicapping the chances for approval of once-daily inhaled Breo (fluticasone furoate /vilanterol) in the wake of last month's FDA advisory panel were surprised by the agency's go-ahead for the chronic obstructive pulmonary disease (COPD) treatment from GlaxoSmithKline plc and Theravance Inc

GlaxoSmithKline plc (London) UMEC/VI A combination of GSK573719, or umeclidinium bromide, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2 agonist, administered using the ELLIPTA inhaler Chronic obstructive pulmonary disease Submitted a regulatory application in Japan 4/23/13 MISCELLANEOUS Advanced Cell Technology Inc. (Marlborough, Mass.) hESC-RPE Human embryonic stem cell-derived retinal pigment epithelial cells Stargardt's macular dystrophy The first subject in the

GlaxoSmithKline plc (London) Breo Fluticasone furoate (FF)/vilanterol (VI), the combination corticosteroid and long-acting beta2 agonist Chronic obstructive pulmonary disease FDA committee recommended approval 4/18/13 Tris Pharma Inc. (Monmouth Junction, N.J.) Karbinal ER Carbinoxamine maleate extended-release oral suspension Seasonal and perennial allergic rhinitis FDA approved it 4/4/13 MISCELLANEOUS Enlivex Therapeutics Ltd. (Jerusalem) ApoCell A treatment based on inducing immune tolerance

and $7.5 million from partner GlaxoSmithKline plc (GSK) for initiation of a Phase II/III study of ISIS-TTRRX in TTR amyloidosis

GlaxoSmithKline plc's initiative on data transparency took a decisive step forward Tuesday as the company switched on the website that will act as the point of access to its vast repositories of clinical data and named the independent review panel who will control that access

was terminated following HGS' acquisition by GlaxoSmithKline plc

Liquidia's business, meanwhile, remains focused on the vaccine and pulmonary product development platform, including work initiated under its 2012 collaboration with London-based GlaxoSmithKline plc

Despite the recent prominence of TLR biology – Bruce Beutler and Jules Hoffman shared one-half of the 2011 Nobel Prize for their seminal discoveries in the area – it has so far proved to be a less fertile ground for drug companies, with the sole exception being London-based GlaxoSmithKline plc's vaccine adjuvant monophosphoryl lipid A (MPL), a TLR-4 agonist

OBT has ongoing drug development deals with London-based GlaxoSmithKline plc and with Paris-based Sanofi SA